GENE THERAPY

Antisense oligonucleotides for atherosclerotic disease

Novel RNA-targeting antisense therapy is shown to reduce lipoprotein(a) levels in 286 patients with existing atherosclerotic disease by upwards of 80% in a phase 2 clinical trial.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: An oligonucleotide for atherosclerosis.

References

  1. 1.

    Tsimikas, S. et al. J. Am. Coll. Cardiol. 71, 177–192 (2018).

    CAS  Article  Google Scholar 

  2. 2.

    Tsimikas, S. et al. N. Engl. J. Med. 382, 244–255 (2020).

    CAS  Article  Google Scholar 

  3. 3.

    Paré, G. et al. Circulation 139, 1472–1482 (2019).

    Article  Google Scholar 

  4. 4.

    Clarke, R. et al. N. Engl. J. Med. 361, 2518–2528 (2009).

    CAS  Article  Google Scholar 

  5. 5.

    Burgess, S. et al. JAMA Cardiol. 3, 619–627 (2018).

    Article  Google Scholar 

  6. 6.

    Thanassoulis, G. et al. N. Engl. J. Med. 368, 503–512 (2013).

    CAS  Article  Google Scholar 

  7. 7.

    de Oliveira Sá, M. P. B. et al. Curr. Atheroscler. Rep. 22, 2 (2020).

    Article  Google Scholar 

  8. 8.

    Boffa, M. B. & Koschinsky, M. L. Nat. Rev. Cardiol. 16, 305–318 (2019).

    Article  Google Scholar 

  9. 9.

    Willeit, P. et al. Lancet 392, 1311–1320 (2018).

    CAS  Article  Google Scholar 

  10. 10.

    Wilson, D. P. et al. J. Clin. Lipidol. 13, 374–392 (2019).

    Article  Google Scholar 

  11. 11.

    Varvel, S., McConnell, J. P. & Tsimikas, S. Arterioscler. Thromb. Vasc. Biol. 36, 2239–2245 (2016).

    CAS  Article  Google Scholar 

  12. 12.

    O’Donoghue, M. L. et al. Circulation 139, 1483–1492 (2019).

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Daniel J. Rader.

Ethics declarations

Competing interests

D. J. R. serves on the Scientific Advisory Board for Alnylam, which makes small interfering RNA therapeutics, and for Novartis, which has licensed AKCEA-APO(a)-LRx.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bajaj, A., Rader, D.J. Antisense oligonucleotides for atherosclerotic disease. Nat Med 26, 471–472 (2020). https://doi.org/10.1038/s41591-020-0835-2

Download citation